Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 242-828-7 | CAS number: 19125-99-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- secondary literature
- Justification for type of information:
- Data is from HPVIS document
Data source
Reference
- Reference Type:
- secondary source
- Title:
- Reproductive toxicity for CAS 550-77-4
- Author:
- U.S Environmental Protection agency
- Year:
- 2 017
- Bibliographic source:
- High Production Volume Information System (HPVIS)
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- not specified
Test material
- Reference substance name:
- N-methylphthalimide
- EC Number:
- 208-982-4
- EC Name:
- N-methylphthalimide
- Cas Number:
- 550-44-7
- Molecular formula:
- C9H7NO2
- IUPAC Name:
- 2-methyl-1H-isoindole-1,3(2H)-dione
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: CD® (SD)
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Analytical verification of doses or concentrations:
- not specified
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day
- Dose / conc.:
- 50 mg/kg bw/day
- Dose / conc.:
- 150 mg/kg bw/day
- Dose / conc.:
- 600 mg/kg bw/day
- No. of animals per sex per dose:
- 20
- Control animals:
- yes, concurrent vehicle
Examinations
- Parental animals: Observations and examinations:
- Clinical signs, Mortality, Body weight, Food consumption, Organ weights
- Oestrous cyclicity (parental animals):
- no data
- Sperm parameters (parental animals):
- no data
- Litter observations:
- yes
- Postmortem examinations (parental animals):
- Gross pathology and Histopathology
- Postmortem examinations (offspring):
- Gross pathology and Histopathology
- Reproductive indices:
- yes
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Ataxia, audible breathing, and piloerection were observed in the high-dose group. "Rooting" and salivation were seen in the mid- and high-dose groups and considered to be a response to taste aversion to the dosing solutions and not an indication of toxicity
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- There were 4 unscheduled, treatment related deaths during the peri-parturitional period for the F0 females at 600 mg/kg/day and most likely due to significant overdosing of the F0 dams during that period.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- F0 females exhibited reduced body weights during gestation and lactation at 600 mg/kg/day. Weight gain during gestation was also reduced at 600 mg/kg/day, but weight gain during lactation was significantly increased at 150 and 600 mg/kg/day, indicating possible rebound even with continued exposure.
F0 females exhibited reduced body weights during gestation and lactation at 600 mg/kg/day. Weight gain during gestation was also reduced at 600 mg/kg/day, but weight gain during lactation was significantly increased at 150 and 600 mg/kg/day, indicating possible rebound even with continued exposure. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Feed consumption, was decreased at 600 mg/kg/day during prebreed in F0 males.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Average pupil size score was reduced in wk 1 (prebreed) at 600 mg/kg/day, and the percentages of F0 females with abnormal arousal were increased at 600 mg/kg/day for wks 3 and 4 (mating and early gestation). The relationship and biological significance of changes in these two parameters at 600 mg/kg/day are unknown.
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Total cholesterol values were significantly increased at 600 mg/kg/day. Average pupil size score was reduced in wk 1 (prebreed) at 600 mg/kg/day, and the percentages of F0 females with abnormal arousal were increased at 600 mg/kg/day for wks 3 and 4 (mating and early gestation). The relationship and biological significance of changes in these two parameters at 600 mg/kg/day are unknown.
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- centrilobular hepatocellular hypertrophy in the liver at 600 mg/kg/day (but not at 150 or 0 mg/kg/day), which was consistent with the increased liver weights at this dose in both sexes, and hyaline droplets in the kidneys of all males at 600 mg/kg/day (none noted at 0 or 150 mg/kg/day).
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- effects observed, treatment-related
- Description (incidence and severity):
- The deaths of 4 dams (out of 10 pregnant) at 600 mg/kg/day, one each on gd 22 and lactational days 2, 3, and 6 are considered treatment related and evidence that this dose exceeded the maximum tolerated dose in this study design of F0 female reproductive toxicity. Precoital interval was significantly decreased at 600 mg/kg/day (the significance, if any, of a shorter precoital interval of 1.4 days is not known). There were no effects on gestational length or reproductive indices. There were significant decreases for the number of total implantation sites per litter and the number of total and live pups per litter at birth (pnd 0) at 600 mg/kg/day.
Details on results (P0)
Males: No mortality. Clinical signs: ataxia, audible breathing, and piloerection were observed in the high-dose group. "Rooting" and salivation were seen in the mid- and high-dose groups and considered to be a response to taste aversion to the dosing solutions and not an indication of toxicity, per se. Since there was a dose-related response, it is presumed that PI, was resulting in the adverse taste. Rooting in bedding, especially postdosing, is observed frequently in gavage studies in the laboratory in a dose-related incidence, consistent with dose-related taste aversion. Feed consumption, was decreased at 600 mg/kg/day during prebreed in F0 males. Liver weights, both absolute and relative to terminal body and brain weight, were significantly increased at 600 mg/kg/day in F0 males. Other potentially treatment-related findings in the F0 males included significantly decreased prostate weight, absolute and relative to terminal body weight at 600 mg/kg/day, and total cholesterol values significantly increased at 600 mg/kg/day. There were no treatment-related effects for the gross necropsy findings. Histological findings included centrilobular hepatocellular hypertrophy in the liver at 600 mg/kg/day (but not at 150 or 0 mg/kg/day), which was consistent with the increased liver weights at this dose in both sexes, and hyaline droplets in the kidneys of all males at 600 mg/kg/day (none noted at 0 or 150 mg/kg/day). All other statistically significant changes were not considered treatment related, based on the lack of dose response. In the male recovery group, body weights were decreased by day 28 (lower than control) but not statistically significantly at the end of recovery. No other signs of toxicity were observed for the recovery group males.
Females: There were 4 unscheduled, treatment related deaths during the peri-parturitional period for the F0 females at 600 mg/kg/day and most likely due to significant overdosing of the F0 dams during that period. Dosing volumes were adjusted during pregnancy, based on each dam's most recent body weight on gd 0, 7, 14, and 20, but the large "maternal" weight gain from gd 14 to 20 (~ 30%) was due to the growth of the uterine contents and not to any appreciable weight gain of the extra-uterine maternal animal. Therefore, the dosing volume set on gd 20, and used until pnd 0, was greatly increased (~ 30%) over the volume used from gd 14-20 and most likely overwhelmed the metabolic capacity of the maternal liver, confounded by increased absorption (from reduced motility and therefore longer transit time) from the gastrointestinal tract late in gestation. F0 females exhibited reduced body weights during gestation and lactation at 600 mg/kg/day. Weight gain during gestation was also reduced at 600 mg/kg/day, but weight gain during lactation was significantly increased at 150 and 600 mg/kg/day, indicating possible rebound even with continued exposure. Feed consumption was significantly decreased during prebreeding, gestation, and lactation at 600 mg/kg/day, but decreased at 150 mg/kg/day only during prebreeding. Total cholesterol values were significantly increased at 600 mg/kg/day. Average pupil size score was reduced in wk 1 (prebreed) at 600 mg/kg/day, and the percentages of F0 females with abnormal arousal were increased at 600 mg/kg/day for wks 3 and 4 (mating and early gestation). The relationship and biological significance of changes in these two parameters at 600 mg/kg/day are unknown.
F0 Parental Reproductive Toxicity: The table below presents a summary of F0 parental reproductive toxicity. The deaths of 4 dams (out of 10 pregnant) at 600 mg/kg/day, one each on gd 22 and lactational days 2, 3, and 6 are considered treatment related and evidence that this dose exceeded the maximum tolerated dose in this study design of F0 female reproductive toxicity. Precoital interval was significantly decreased at 600 mg/kg/day (the significance, if any, of a shorter precoital interval of 1.4 days is not known). There were no effects on gestational length or reproductive indices. There were significant decreases for the number of total implantation sites per litter and the number of total and live pups per litter at birth (pnd 0) at 600 mg/kg/day.
Effect levels (P0)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- food consumption and compound intake
- ophthalmological examination
- clinical biochemistry
- Dose descriptor:
- NOAEL
- Effect level:
- >= 600 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- reproductive performance
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- reproductive performance
Target system / organ toxicity (P0)
- Critical effects observed:
- not specified
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not specified
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- There was 1 unscheduled death each for adult F1 males at 50 and 600 mg/kg/day. Both unscheduled deaths were due to a dosing error and were not considered related to treatment.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- There were significant reductions in body weight and weight gain for the F1 males during the postweaning period (from pnd 22 to 71) at all dose levels. However, there was no dose-response relationship in the body weight reductions for the low- and mid-dose groups; the males at the low dose exhibited lower body weights than the males at the mid dose. Consistent with the reduced body weights at all doses for F1 males, the absolute and adjusted ages at acquisition of puberty (PPS) were also significantly delayed in all treated groups. These slight but statistically significant delays for absolute age (2.3, 4.1, and 5.0) and for adjusted age (2.3, 3.3, and 5.2) at 50, 150, and 600 mg/kg/day, respectively, are most likely due to the reduced body weights during this time in all PI groups.
Significantly lower mean body weights occurred at 150 and 600 mg/kg/day for the F1 females throughout the postweaning period (from pnd 22 to 71). Consistent with the reduced body weights at 600 mg/kg/day, age at acquisition of puberty (VP) was also significantly delayed at 600 mg/kg/day by 3.0 days for absolute age and by 3.1 days for adjusted age. This delay at 600 mg/kg/day is most likely due to the reduced body weights at this dose during this time. Body weight gains were significantly decreased at 150 mg/kg/day for the F1 females only during the first week of the postweaning period (from pnd 22 to 29). - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Feed consumption, expressed as g/day, was significantly decreased at all dose levels during the postweaning period. However, there were no significant changes in feed consumption expressed as g/kg/day at any dose level, suggesting the reduced feed consumption was correlated with (likely due to) the reduced body weights in all groups. As with the males, there were no significant differences in feed consumption values expressed as g/kg/day.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- hemoglobin values were statistically increased at 600 mg/kg/day. Platelet count values were statistically decreased at 150 and 600 mg/kg/day, and the mean platelet volume values were statistically decreased at all dose levels.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Total cholesterol was increased at 600 mg/kg/day for the F1 females.
- Urinalysis findings:
- not specified
- Sexual maturation:
- effects observed, treatment-related
- Description (incidence and severity):
- Delayed acquisition of puberty in both F1 sexes
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- At scheduled necropsy, body weights were significantly decreased at 50, 150, and 600 mg/kg/day. Reduced absolute organ weights were likely due to the reduced body weights, since organ weights relative to body or brain weights were either unaffected or increased. The increase in liver weights, relative to terminal body weights at 600 mg/kg/day, was most likely related to the lower body weights in this group.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related effects for the gross necropsy findings.
- Histopathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Histological findings included centrilobular hepatocellular hypertrophy in all 5 F1 male livers at 600 mg/kg/day (but not at 0 or 150 mg/kg/day), although there was no associated liver weight increase. In addition, hyaline droplets in all 5 F1 male kidneys at 600 mg/kg/day (but not at 0 or 150 mg/kg/day) were considered treatment related. Histopathological findings included minimal centrilobular hepatocellular hypertrophy in all 5 F1 female livers at 600 mg/kg/day, but no such findings at 0 or 150 mg/kg/day.
- Other effects:
- not specified
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not specified
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not specified
Details on results (F1)
Females: There were no unscheduled deaths for the adult F1 females. Significantly lower mean body weights occurred at 150 and 600 mg/kg/day for the F1 females throughout the postweaning period (from pnd 22 to 71). Consistent with the reduced body weights at 600 mg/kg/day, age at acquisition of puberty (VP) was also significantly delayed at 600 mg/kg/day by 3.0 days for absolute age and by 3.1 days for adjusted age. This delay at 600 mg/kg/day is most likely due to the reduced body weights at this dose during this time. Body weight gains were significantly decreased at 150 mg/kg/day for the F1 females only during the first week of the postweaning period (from pnd 22 to 29). Feed consumption values expressed as g/day were decreased at 150 and 600 mg/kg/day. As with the males, there were no significant differences in feed consumption values expressed as g/kg/day. In addition, there were no significant differences in the duration of estrous cycles across all groups and no treatment-related changes in FOB measurements. At necropsy, terminal body weights were significantly decreased at 600 mg/kg/day. The increase in liver weights, relative to terminal body weights at 600 mg/kg/day, was most likely related to the lower body weights in this group. Total cholesterol was increased at 600 mg/kg/day for the F1 females. There were no treatment-related effects for the gross necropsy findings. Histopathological findings included minimal centrilobular hepatocellular hypertrophy in all 5 F1 female livers at 600 mg/kg/day, but no such findings at 0 or 150 mg/kg/day.
F1 Offspring Toxicity: There was evidence of F1 offspring toxicity at 600 mg/kg/day, expressed as reduced pup body weights per litter on pnd 7 (males only), 14 (males, females, and all pups), and 21 (males and all pups). The stillbirth index at 600 mg/kg/day was increased, but not statistically significantly, due to inclusion of a litter born dead on pnd 0. Therefore, the live birth index at 600 mg/kg/day was also decreased through lactation, but not statistically significantly. There were no effects on anogenital distance at birth, sex ratio (% males) per litter, or retention of nipples/areolae for preweanling male pups on pnd 11-13. Acquisition of F1 male PPS was significantly delayed across all dose groups and was considered treatment related. F1 female vaginal opening was significantly delayed at 600 mg/kg/day and was considered treatment related. Delayed acquisition of puberty in both F1 sexes was most likely due to the reduced body weights for F1 postweanling males in all PI-exposed groups and the reduced body weights for F1 postweanling females at 600 mg/kg/day during the peripubertal period. There were significant decreases in body weights at sacrifice observed at 600 mg/kg/day in both F1 males and females on pnd 21. Absolute spleen weights were significantly decreased in the F1 males on pnd 21. Brain weights, relative to terminal body weights, were significantly increased at 600 mg/kg/day (but not at any other dose level) for the F1 males. Paired epididymal weights, relative to body weight, were significantly increased at 600 mg/kg/day for the F1 males. Absolute thymus and spleen weights were significantly decreased at 600 mg/kg/day for the F1 females. Brain weight, relative to body weight, was significantly increased at 600 mg/kg/day for the F1 females. Thymus and spleen weights, relative to terminal brain weights, were significantly decreased for the F1 females at 600 mg/kg/day. There were no treatment-related findings at necropsy of the F1 pups on pnd 21.
Effect levels (F1)
open allclose all
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- < 50 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- other: delays in acquisition of puberty at all doses
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 50 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- body weight and weight gain
- other: delay in acquisition of puberty at 600 mg/kg/day
Target system / organ toxicity (F1)
- Critical effects observed:
- not specified
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Reproductive toxicity was evaluated for the substance 2-methyl-1H-isoindole-1,3(2H)-dione. The F0 male and female systemic No observable adverse effect level (NOAEL) was 150 mg/kg/day. The F1 male systemic NOAEL was less than 50 mg/kg/day, and the F1 female systemic NOAEL was 50 mg/kg/day (both due to reduced body weights at higher doses). The NOAELs for F0 reproductive toxicity were at or above 600 mg/kg/day for males and 150 mg/kg/day for females (due to periparturitional demise and to reduced total implants/litter and reduced total and live litter sizes at birth at 600 mg/kg/day). The NOAELs for F1 offspring toxicity were less than 50 mg/kg/day for males (due to reduced postweaning body weights and delays in acquisition of puberty at all PI doses) and at 50 mg/kg/day for females (due to reduced postwean body weights at 150 and 600 mg/k g/day and delay in acquisition of puberty at 600 mg/kg/day).
- Executive summary:
The substance2-methyl-1H-isoindole-1,3(2H)-dioneadministered by gavage once daily at 0, 50, 150, and 600 mg/kg/day to parental F0 CD® (SD) rats, 10/sex/group, through prebreed, mating, gestation, and lactation and direct dosing to F1 offspring from weaning to scheduled sacrifice, resulted in adult F0 parental toxicity at 600 mg/kg/day, which was more severe in females than in males. Toxicity was present in F0 females at 600 mg/kg/day was expressed as periparturtional demise in 4 of the 10 pregnant females and reduced total and live litter size at birth. There was F1 offspring toxicity observed postnatally, expressed as reduced pup body weights per litter during lactation in both sexes, and centrilobular hepatocellular hypertrophy in F1 males and females at 600 mg/kg/day, and hyaline droplets in the kidneys of the F1 adult males at 600 mg/kg/day. In addition, F1 postweanlings exhibited reduced body weights at 150 and 600 mg/kg/day for females and at 50, 150, and 600 mg/kg/day for males. Acquisition of puberty in F1 males was significantly delayed at 50, 150, and 600 mg/kg/day and in F1 females at 600 mg/kg/day, associated with reduced body weights during the postwean retention period at all 3 doses for F1 males and at the top dose for F1 females.The F0 male and female systemic No observable adverse effect level (NOAEL) was 150 mg/kg/day. The F1 male systemic NOAEL was less than 50 mg/kg/day, and the F1 female systemic NOAEL was 50 mg/kg/day (both due to reduced body weights at higher doses). The NOAELs for F0 reproductive toxicity were at or above 600 mg/kg/day for males and 150 mg/kg/day for females (due to periparturitional demise and to reduced total implants/litter and reduced total and live litter sizes at birth at 600 mg/kg/day). The NOAELs for F1 offspring toxicity were less than 50 mg/kg/day for males (due to reduced postweaning body weights and delays in acquisition of puberty at all the doses) and at 50 mg/kg/day for females (due to reduced postwean body weights at 150 and 600 mg/k g/day and delay in acquisition of puberty at 600 mg/kg/day).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.